{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:29:29Z","timestamp":1793773769971,"version":"4.6.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["184.034.019"],"award-info":[{"award-number":["184.034.019"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["#14465"],"award-info":[{"award-number":["#14465"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017851","name":"Sebia","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100017851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health\u223cHolland","doi-asserted-by":"publisher","award":["LSHM21032"],"award-info":[{"award-number":["LSHM21032"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2023-0781_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Minimal residual disease status in multiple myeloma is an important prognostic biomarker. Recently, personalized blood-based targeted mass spectrometry (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to measure minimal residual disease. However, quantification of MS-MRD requires a unique calibrator for each patient. The use of patient-specific stable isotope labelled (SIL) peptides is relatively costly and time-consuming, thus hindering clinical implementation. Here, we introduce a simplification of MS-MRD by using an\u00a0off-the-shelf calibrator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0781_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SILuMAB-based MS-MRD was performed by spiking a monoclonal stable isotope labeled IgG, SILuMAB-K1, in the patient serum. The abundance of both M-protein-specific peptides and SILuMAB-specific peptides were monitored by mass spectrometry. The relative ratio between M-protein peptides and SILuMAB peptides allowed for M-protein quantification. We assessed linearity, sensitivity and reproducibility of SILuMAB-based MS-MRD in longitudinally collected sera from the IFM-2009 clinical trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0781_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A linear dynamic range was achieved of over 5 log\u00a0scales, allowing for M-protein quantification down to 0.001\u202fg\/L. The inter-assay CV of SILuMAB-based MS-MRD was\u00a0on average 11\u202f%. Excellent concordance between SIL-\u00a0and SILuMAB-based MS-MRD was shown (R<jats:sup>2<\/jats:sup>&gt;0.985). Additionally, signal intensity of spiked SILuMAB can be used for quality control purpose to assess system performance and incomplete SILuMAB digestion can be used as quality control for sample preparation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0781_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared to SIL peptides, SILuMAB-based MS-MRD improves the reproducibility, turn-around-times and cost-efficacy of MS-MRD without diminishing its sensitivity and specificity. Furthermore, SILuMAB can be used as\u00a0a MS-MRD quality control tool to monitor sample preparation efficacy and assay performance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2023-0781","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T10:32:11Z","timestamp":1697106731000},"page":"540-550","source":"Crossref","is-referenced-by-count":11,"title":["M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator"],"prefix":"10.1515","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8751","authenticated-orcid":false,"given":"Charissa","family":"Wijnands","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Langerhorst","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayya","family":"Noori","sequence":"additional","affiliation":[{"name":"Department of Neurology , Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenneke","family":"Keizer-Garritsen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.C.T.","family":"Wessels","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolein","family":"Gloerich","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bonifay","sequence":"additional","affiliation":[{"name":"Sebia , Lisses , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Caillon","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, Hospital of Nantes , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"Luider","sequence":"additional","affiliation":[{"name":"Department of Neurology , Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain J.","family":"van Gool","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dejoie","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, Hospital of Nantes , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-994X","authenticated-orcid":false,"given":"Martijn M.","family":"VanDuijn","sequence":"additional","affiliation":[{"name":"Department of Neurology , Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannes F.M.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"2024012313272696326_j_cclm-2023-0781_ref_001","doi-asserted-by":"crossref","unstructured":"van de Donk, N, Pawlyn, C, Yong, KL. Multiple myeloma. Lancet 2021;397:410\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_002","doi-asserted-by":"crossref","unstructured":"Moreau, P, Attal, M, Facon, T. Frontline therapy of multiple myeloma. Blood 2015;125:3076\u201384. https:\/\/doi.org\/10.1182\/blood-2014-09-568915.","DOI":"10.1182\/blood-2014-09-568915"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_003","doi-asserted-by":"crossref","unstructured":"Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_004","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M, Kyle, R, Fermand, JP, Rajkumar, SV, San Miguel, J, Chanan-Khan, A, et al.. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701\u20135. https:\/\/doi.org\/10.1182\/blood-2010-10-299529.","DOI":"10.1182\/blood-2010-10-299529"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_005","doi-asserted-by":"crossref","unstructured":"Murray, DL, Surendra, D. Clinical mass spectrometry approaches to myeloma and amyloidosis. Clin Lab Med 2021;41:203\u201319. https:\/\/doi.org\/10.1016\/j.cll.2021.03.003.","DOI":"10.1016\/j.cll.2021.03.003"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_006","doi-asserted-by":"crossref","unstructured":"Dasari, S, Kohlhagen, MC, Dispenzieri, A, Willrich, MAV, Snyder, MR, Kourelis, TV, et al.. Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases. Mayo Clin Proc 2022;97:294\u2013304. https:\/\/doi.org\/10.1016\/j.mayocp.2021.07.024.","DOI":"10.1016\/j.mayocp.2021.07.024"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_007","doi-asserted-by":"crossref","unstructured":"Wijnands, C, Noori, S, Donk, NWCJV, VanDuijn, MM, Jacobs, JFM. Advances in minimal residual disease monitoring in multiple myeloma. Crit Rev Clin Lab Sci 2023;26:1\u201317. https:\/\/doi.org\/10.1080\/10408363.2023.2209652.","DOI":"10.1080\/10408363.2023.2209652"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_008","doi-asserted-by":"crossref","unstructured":"Murray, DL. Brining mass spectrometry into the care of patients with multiple myeloma. 2022;115:790-8, https:\/\/doi.org\/10.1007\/s12185-022-03364-2.","DOI":"10.1007\/s12185-022-03364-2"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_009","doi-asserted-by":"crossref","unstructured":"Liyasova, M, McDonald, Z, Taylor, P, Gorospe, K, Xu, X, Yao, C, et al.. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res 2021;27:5028\u201337. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-0649.","DOI":"10.1158\/1078-0432.CCR-21-0649"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_010","doi-asserted-by":"crossref","unstructured":"Martins, CO, Huet, S, Yi, SS, Ritorto, MS, Landgren, O, Dogan, A, et al.. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn 2020;22:901\u201311. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.04.002.","DOI":"10.1016\/j.jmoldx.2020.04.002"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_011","doi-asserted-by":"crossref","unstructured":"Zajec, M, Jacobs, JFM, Groenen, PJTA, de Kat Angelino, CM, Stingl, C, Luider, TM, et al.. Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J Proteome Res 2018;17:1326\u201333. https:\/\/doi.org\/10.1021\/acs.jproteome.7b00890.","DOI":"10.1021\/acs.jproteome.7b00890"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_012","doi-asserted-by":"crossref","unstructured":"Di Noia, JM, Neuberger, MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007;76:1\u201322. https:\/\/doi.org\/10.1146\/annurev.biochem.76.061705.090740.","DOI":"10.1146\/annurev.biochem.76.061705.090740"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_013","doi-asserted-by":"crossref","unstructured":"Dudley, DD, Chaudhuri, J, Bassing, CH, Alt, FW. Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv Immunol 2005;86:43\u2013112. https:\/\/doi.org\/10.1016\/S0065-2776(04)86002-4.","DOI":"10.1016\/S0065-2776(04)86002-4"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_014","doi-asserted-by":"crossref","unstructured":"Langerhorst, P, Noori, S, Zajec, M, de Rijke, YB, Gloerich, J, van Gool, AJ, et al.. Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow. Clin Chem 2021;67:1689\u201398. https:\/\/doi.org\/10.1093\/clinchem\/hvab187.","DOI":"10.1093\/clinchem\/hvab187"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_015","doi-asserted-by":"crossref","unstructured":"Zajec, M, Langerhorst, P, VanDuijn, MM, Gloerich, J, Russcher, H, van Gool, AJ, et al.. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin Chem 2020;66:421\u201333. https:\/\/doi.org\/10.1093\/clinchem\/hvz041.","DOI":"10.1093\/clinchem\/hvz041"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_016","doi-asserted-by":"crossref","unstructured":"Noori, S, Wijnands, C, Langerhorst, P, Bonifay, V, Stingle, C, Touzeau, C, et al.. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry [Letter]. Blood Cancer J 2023;13:30. https:\/\/doi.org\/10.1038\/s41408-023-00803-z.","DOI":"10.1038\/s41408-023-00803-z"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_017","doi-asserted-by":"crossref","unstructured":"Lange, V, Picotti, P, Domon, B, Aebersold, R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008;4:1\u201314. https:\/\/doi.org\/10.1038\/msb.2008.61.","DOI":"10.1038\/msb.2008.61"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_018","doi-asserted-by":"crossref","unstructured":"Jones, KA, Kim, PD, Patel, BB, Kelsen, SG, Braverman, A, Swinton, DJ, et al.. Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite\/LTQ-Orbitrap Velos\/Q exactive mass spectrometers. J Proteome Res 2013;12:4351\u201365. https:\/\/doi.org\/10.1021\/pr400307u.","DOI":"10.1021\/pr400307u"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_019","doi-asserted-by":"crossref","unstructured":"McDonald, Z, Taylor, P, Liyasova, M, Liu, Q, Ma, B. Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients. J Proteome Res 2021;20:4176\u201385. https:\/\/doi.org\/10.1021\/acs.jproteome.0c01022.","DOI":"10.1021\/acs.jproteome.0c01022"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_020","doi-asserted-by":"crossref","unstructured":"Attal, M, Lauwers-Cances, V, Hulin, C, Leleu, X, Caillot, D, Excoffre, M, et al.. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:1311\u201320. https:\/\/doi.org\/10.1056\/nejmoa1611750.","DOI":"10.1056\/NEJMoa1611750"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_021","doi-asserted-by":"crossref","unstructured":"Langerhorst, P, Brinkman, AB, VanDuijn, MM, Wessels, HJCT, Groenen, PJTA, Joosten, I, et al.. Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma. Clin Chem 2021;67:867\u201375. https:\/\/doi.org\/10.1093\/clinchem\/hvab017.","DOI":"10.1093\/clinchem\/hvab017"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_025","doi-asserted-by":"crossref","unstructured":"Noori, S, Zajec, M, Russcher, H, Tintu, AN, Broijl, A, Jacobs, JFM, et al.. Retrospective longitudinal monitoring of multiple myeloma patients by mass spectrometry using archived serum protein electrophoresis gels and de novo sequence analysis. Hemasphere 2022;6:e758. https:\/\/doi.org\/10.1097\/hs9.0000000000000758.","DOI":"10.1097\/HS9.0000000000000758"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_022","doi-asserted-by":"crossref","unstructured":"Jacobs, JFM, Turner, KA, Graziani, MS, Frinack, JL, Ettore, MW, Tate, JR, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med 2020;58:547\u201359. https:\/\/doi.org\/10.1515\/cclm-2019-1105.","DOI":"10.1515\/cclm-2019-1105"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_023","doi-asserted-by":"crossref","unstructured":"Turner, KA, Frinack, JL, Ettore, MW, Tate, JR, Graziani, MS, Jacobs, JFM, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med 2020;58:533\u201346.","DOI":"10.1515\/cclm-2019-1104"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_024","unstructured":"Food and Drug Administration. Bioanalytical method validation guidance for industry. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf [Accessed January 2023]."},{"key":"2024012313272696326_j_cclm-2023-0781_ref_026","doi-asserted-by":"crossref","unstructured":"Noori, S, Verkleij, CPM, Zajec, M, Langerhorst, P, Bosman, PWC, de Rijke, YB, et al.. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clin Chem Lab Med 2021;59:1963\u201371. https:\/\/doi.org\/10.1515\/cclm-2021-0399.","DOI":"10.1515\/cclm-2021-0399"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_027","unstructured":"Hustoft, HK, Malerod, H, Wilson, SR, Reubsaet, L, Lundanes, E, Greibrokk, T. A critical review of trypsin digestion for LC-MS based proteomics. In: Leung, HCE, Man, TK, Flores, RJ, editors. Integrative proteomics. Rijeka: IntechOpen; 2012:73\u201392 pp."},{"key":"2024012313272696326_j_cclm-2023-0781_ref_028","doi-asserted-by":"crossref","unstructured":"Zheng, W, Yang, P, Sun, C, Zhang, Y. Comprehensive comparison of sample preparation workflows for proteomics. Mol Omics 2022;18:555\u201367. https:\/\/doi.org\/10.1039\/d2mo00076h.","DOI":"10.1039\/D2MO00076H"},{"key":"2024012313272696326_j_cclm-2023-0781_ref_029","doi-asserted-by":"crossref","unstructured":"de Kat Angelino, CM, Jacobs, JFM. External quality assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification. Clin Chem Lab Med 2021;59:1063\u20138. https:\/\/doi.org\/10.1515\/cclm-2020-1810.","DOI":"10.1515\/cclm-2020-1810"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0781\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T13:31:14Z","timestamp":1706016674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0781\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,13]]},"published-print":{"date-parts":[[2024,2,26]]}},"alternative-id":["10.1515\/cclm-2023-0781"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2023-0781","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}